Tucker v. SmithKline Beecham Corp.’s Empirical Analysis
2008
Citation profile
2 federal appellate ·
Relationships
Applies 21 U.S.C. § 331 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 332 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 352 (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 360K (Federal Food, Drug, and Cosmetic Act) · 21 U.S.C. § 382 (Federal Food, Drug, and Cosmetic Act)
Relies on Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc. · Skidmore v. Swift & Co. · United States v. Mead Corp. · Medtronic, Inc. v. Lohr · Fidelity Federal Savings and Loan Association v. D Cuesta
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 4 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“In adults with MDD (all ages), there was a statistically significant increase in the frequency of suicidal behavior in patients treated with paroxetine compared luith placebo (11/3,155 [0.32%] versus 1/ 1, 978 [0.05%]); all of the events were suicide attempts. However, the majority of these attempts for paroxetine (8 of 11) were in younger adults aged 18-30 years. These MDD data suggest that the higher frequency observed in the younger adult population across psychiatric disorders may extend beyond the age of 24.”
2 later decisions quote this exact passage“studies did not show an increase in the risk of suicidality ... in adults beyond age 24.”
1 later decision quote this exact passage
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.